OXNARD, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas.

“This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical. “His support and counsel have been and will continue to be instrumental in guiding our growth strategy.”

Dr. Salkind is a prominent investor in the pharmaceutical arena. Past previous successful investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, one of the nation's largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.

“In the past year, CURE has evolved as a leader in the biotechnology field through its continual pursuit of redefining traditional drug delivery,” said Dr. Salkind. “We want to continue this momentum and pave the way for more partnerships and product offerings that will transform the medical field in association with CURE.

About CURE Pharmaceuticals
CURE Pharmaceutical is a fully integrated drug delivery and development committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.

This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Inquiries:
Ashley Ray
310.824.9000
[email protected]